ELDNEledon Pharmaceuticals Inc
$3.62
$0.05
(1.40%)
Pre-Market
Reported EarningsMay 13
Mkt Cap$275.56M
Vol89,467.00
Fundamentals
Mkt Cap
$275.56M
Volume
-
52W High
$4.60
52W Low
$1.35
PE Ratio
-4.16
Avg. Volume
1.12M
EPS (Annual)
-$0.5574
Rev/Employee
$0.00
Earnings
May 13
71
Bullish Sentiment
How do you feel about ELDN?
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Zacks
Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday
Eledon Pharmaceuticals (NASDAQ:ELDN) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-eledon-pharmaceuticals-inc-stock...
MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five ratings firms that are covering the firm, Marketbeat reports. One...
MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 14.5% in March
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 7,193,953...
MarketBeat
SG Americas Securities LLC Makes New Investment in Eledon Pharmaceuticals, Inc. $ELDN
SG Americas Securities LLC bought a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and...
MarketBeat
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines PR Newswire VANCOUVER, BC, April 6, 2026 Issued on behalf...
PR Newswire
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3%
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 8,417,915 shares, an...
MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) has received an average recommendation of "Hold" from the five brokerages that are presently covering the firm, Marketbeat.com reports...
MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.10...
MarketBeat
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) used a presentation at the Leerink Partners Global Healthcare Conference to highlight what CEO David-Alexandre Gros described as a rapid expansion in clinical...
MarketBeat
<
1
2
...
>